# Reversal to Normoglycemia by Treating Prediabetes

Study · id `cardio:ct-nct07392151` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07392151](<https://clinicaltrials.gov/study/NCT07392151>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07392151

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 158 participants.

## Technical summary

Registry record NCT07392151. Randomized; no masking; primary purpose prevention. Start 2026-02 (anticipated); primary completion 2029-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 158 participants (planned count; ClinicalTrials.gov record NCT07392151, source copy `cardio:ctgov-nct07392151-2026-02-06`, retrieved 2026-10-26)
- Planned start: 2026-02 (anticipated) (ClinicalTrials.gov record NCT07392151, source copy `cardio:ctgov-nct07392151-2026-02-06`, retrieved 2026-10-26)
- Primary completion: 2029-10 (anticipated) (ClinicalTrials.gov record NCT07392151, source copy `cardio:ctgov-nct07392151-2026-02-06`, retrieved 2026-10-26)
- Completion: 2029-10 (anticipated) (ClinicalTrials.gov record NCT07392151, source copy `cardio:ctgov-nct07392151-2026-02-06`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT07392151, source copy `cardio:ctgov-nct07392151-2026-02-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07392151-2026-02-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Reversal to Normoglycemia by Treating Prediabetes
- Condition: Prediabetes
- Condition: Chronic Coronary Syndrome
- Intervention (Drug): Intensified medical follow-up and glucose-lowering drugs
- Intervention (Other): No intervention
- Lead sponsor: Michael Mæng
- Lead sponsor class: OTHER
- Collaborator: Aarhus University Hospital
- Collaborator class: OTHER
- Collaborator: GCP-unit at Aarhus University Hospital, Aarhus, Denmark
- Collaborator class: OTHER
- Collaborator: Department of Clinical Epidemiology, Aarhus University, DK-8200 Aarhus N, Denmark
- Collaborator class: UNKNOWN
- Collaborator: University of Aarhus
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as a collaborator: Aarhus University Hospital (`cardio:org-aarhus-university-hospital`)
- Registry lists this organization as a collaborator: University of Aarhus (`cardio:org-university-of-aarhus`)

## Provenance

Content hash: b351720761eb408eceb3c79f561e016d70da2bb965c848149e6c851b64a69c74
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
